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SObjective: To clarify the perioperative and oncologic outcome of pulmonary resection for a metachronous
second primary lung cancer (MSPLC) following resection of an initial non–small cell lung cancer (NSCLC).
Methods: Retrospective chart review identified 161 patients (88 men and 73 women) with a median age of 70
years (range, 34-88 years) who underwent pulmonary resection for MSPLC between January 2000 and Decem-
ber 2009. Operative morbidity, mortality, and relevant factors were analyzed with c2 test or Fisher exact test and
Mann-Whitney U test. Survival was analyzed with Kaplan-Meier and Cox proportional hazard method.
Results: The median interval between the initial and subsequent resection for MSPLC was 42.7 months (range,
7-205 months). There was no operative mortality and postoperative complication rate was 29%. In multivariate
analysis, ipsilateral operation (P ¼ .0002) and a lower predicted preoperative percent forced expiratory volume
in the first second (P ¼ .0035) were significant risk factors for postoperative complications. Five-year overall
survival rates after resection of the initial and second metachronous NSCLC were 87.4% and 60.8%, respec-
tively. Significant negative long-term prognostic factors for survival following resection of a MSPLC in multi-
variate analysis were tumor size>2 cm (P¼ .003) and number of pack years of smoking (P¼ .005). Metastatic
nodal disease (P ¼ .19) or a sublobar resection (P ¼ .17) were not associated with worse survival.
Conclusions: Surgical treatment of a MSPLC can be undertaken with 5-year survival rate of 60%. Expected
operative morbidity and mortality are comparable to primary surgery. Tumors 2 cm or smaller are associated
with improved survival and freedom from recurrence. Close long-term follow-up of patients who have under-
gone resection of NSCLC is recommended. (J Thorac Cardiovasc Surg 2013;145:683-91)The identification ofmultiple primary lung cancers (MPLCs)
was first described in 1924 by Beyreuther1 who identified 2
separate primary lung cancers in a patientwith pulmonary tu-
berculosis. Since that time there have been many reports of
both synchronous and metachronous lung cancers in the lit-
erature.2-5 However, although the idea of MPLCs has been
generally accepted by thoracic surgeons, this entity is still
relatively uncommon compared with second primary
tumors in other paired organs such as the breast and ovary.2
The discovery of more than 1 pulmonary nodule in a patient
either newly diagnosedwith lung cancer or subsequently fol-
lowing presumed complete resection of non–small cell lung
cancer (NSCLC) raises the clinical dilemmaofwhether these
lesions represent MPLCs with different clonality, recurrent
disease, or intrapulmonary metastases. Because there are
no rigorous clinical or histopathologic criteria that allowe Division of General Thoracic Surgery, Mayo Clinic, Rochester, Minn.
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The Journal of Thoracic and Caone to clearly distinguish between these scenarios, it is not
surprising that estimates of the incidence of MPLC vary
widely. The actual frequency of MPLC is unknown, but pre-
viously published rates range from 0.8% to 14.5% of all
patients with NSCLC, depending on if it was derived from
a cancer registry, autopsy series, or surgical series.3
Although lung cancer remains the leading cause of can-
cer death worldwide, a number of recent advances in early
detection and improvements in adjuvant therapies have
raised hopes that improvements in survival are possible in
the future. This will potentially create a larger population
of patients who have been cured of their index cancer and
are more likely to survive long enough to develop second
and third primary lung cancers. With more aggressive and
vigilant surveillance, early detection of these recurrences
is possible and successful curative management of MPLC
is achievable. The goal of our study was to review our expe-
rience with surgical treatment for patients with metachro-
nous second primary lung cancer (MSPLC) to identify
factors associated with prolonged survival and characteris-
tics that may be useful to distinguish patients with MSPLC
from those with more advanced disease.
PATIENTS AND METHODS
Patient Selection and Study Design
Between January 1, 2000, and December 31, 2009, all patients who
underwent surgical treatment for primary lung cancer at Mayo Clinic,rdiovascular Surgery c Volume 145, Number 3 683
Abbreviations and Acronyms
CT ¼ computed tomography
CXR ¼ chest radiograph
DFI ¼ disease-free interval
FEV1 ¼ forced expiratory volume in the first
second
MPLC ¼ multiple primary lung cancers
MSPLC ¼ metachronous second primary lung
cancer
NSCLC ¼ non–small cell lung cancer
TNM ¼ TNM Classification of Malignant
Tumors
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SRochester, Minn, were identified from a prospectively maintained surgical
database. Information on patients found to have resected MSPLC during
this 10-year period was reviewed. Initial resection of the NSCLC had
been performed at Mayo Clinic as well as other institutions, but all resec-
tions of second primary NSCLC were performed at Mayo Clinic. In 4 of 5
patients whose first operation had not been done at Mayo Clinic, the orig-
inal pathology slides from the first lung cancer were obtained and reviewed
by Mayo pathologists; compared with the subsequent specimens; and were
determined likely to be second primary tumors based on differences in
tumor morphology, histologic features, and degree of differentiation. In
patients who had previously undergone complete resection of a NSCLC,
a subsequent lung neoplasm was considered a second primary lung cancer
when it met the following criteria previously reported by us.4,5 A
carcinoma was considered to be a second primary lung cancer if it was
of a different cell type. A metachronous carcinoma with a cell type
similar to that of the original lesion was considered a new primary lung
cancer when the new lesion occurred outside the area anatomically
contiguous to the previous lung cancer and its regional lymphatics, when
there was no evidence of extrathoracic cancer, and when the new lesion
was solitary in the parenchyma of the lung. The American Joint
Committee for Cancer Staging TNM Classification of Malignant Tumors
(TNM) (in which a stage is assigned based on tumor size, lymph nodes
affected, and metastases) was used to stage the cancer.6,7 Stage
assignment was made based on the TNM scheme that was in effect at the
time the operation was performed. For most of the initial operations, this
was the sixth edition, and for the second operations this was a mix of the
sixth and seventh editions, because our institution switched to using the
seventh edition January 1, 2009. Patients were screened for evidence of
metastatic disease, and only patients classified as having stage M1
disease on the basis of having intrapulmonary ipsilateral tumor in
nonprimary tumor lobe(s) of the lung or isolated brain metastasis with
a disease-free interval>5 years were included. The medical records were
retrospectively reviewed for demographic information, presenting symp-
toms, operative procedures, prior surgery, pathology, morbidity andmortal-
ity, length of hospitalization, adjuvant therapies given, and last follow-up
visit or date of death. Operative mortality included all deaths occurring
within 30 days of the operative procedure and those who died later but dur-
ing the same hospitalization. Survival data not available in the medical re-
cord was obtained from the Social Security Death Index. Follow-up by
chart review and with the primary care physician was performed. Follow-
ing pulmonary resection for an initial NSCLC, the patients were followed
by a thoracic surgeon, pulmonologist, medical oncologist, or primary care
physician with a physical examination along with radiologic imaging such
as a chest radiograph (CXR), computed tomography (CT), or
positron emission test-CT at the discretion of the physician. The Mayo
Foundation Institutional Review Board approved this study with waiver684 The Journal of Thoracic and Cardiovascular Surgof informed consent and waiver of the Health Insurance Portability and Ac-
countability Act.
Statistical Analysis
Descriptive statistics for categorical variables are reported as frequency
and percentage, whereas continuous variables are reported as mean  stan-
dard deviation or median (range) as appropriate. For categorical variables,
comparisons between groups were made using c2 tests or Fisher exact tests
as appropriate. Continuous variables were compared by the Mann-Whitney
U test. All statistical tests were 2-sided withP<.05 defined as achieving sta-
tistical significance. The date of the second lung cancer operation was the
starting point in the survival estimation and the date of death or last follow-
up the end point. All survival rates reported are overall survival rates unless
otherwise noted. For the outcome of time to patient death, univariateCoxpro-
portional hazards models were constructed, assessing clinically interesting
covariates. Long-term survival was estimated using the Kaplan-Meier sur-
vival method. Univariate logistic regression, assessing covariates of clinical
interest, was performed to determine factors associated with increased rates
of postoperative complications, long-term survival after surgical treatment of
the initial NSCLC and the second primary lung cancer, and improved
progression-free interval. Factors analyzed includedpatient sex, smoking his-
tory (never vs former vs current, quit before or after primary lung cancer
operation, number of pack years), disease-free interval (DFI), type of radio-
graphic study used in follow-up surveillance, forced expiratory volume in the
first second (FEV1), tumor size, presence of multiple nodules, surgical
approach, extent of surgical resection, lymph node status, TNM stage, and
histology of second primary lung cancer. Variables considered in themultiple
variablemodelswere thosewith aPvalue .15 in the univariate assessments.
Finalmodels used backwardmodel selection, although for each outcome for-
ward selection and a stepwise procedure confirmed the same model. JMP
version 8.0.1 (SAS Institute, Cary, NC) was used for all analyses.
Patient Characteristics
During the study time period 3148 patients underwent surgical treat-
ment of NSCLC at Mayo Clinic, Rochester, Minn, and 161 patients
(5.1%) underwent surgical treatment of a metachronous second primary
NSCLC following complete resection of a previous lung cancer. The char-
acteristics and operative details of the 161 patients are shown in Table 1.RESULTS
There were no operative deaths. Postoperative complica-
tions occurred in 47 patients (29.2%) and included pro-
longed air leak (defined as >5 days) in 19 patients
(11.8%), atrial fibrillation in 12 patients (7.5%), postoper-
ative pneumonia in 6 patients (3.7%), and respiratory fail-
ure requiring mechanical ventilation in 3 patients (1.9%).
Univariate analysis revealed that a lower than predicted per-
cent FEV1 (P ¼ .0211) and reoperative ipsilateral surgery
(P ¼ .0002) were the only factors associated with an in-
creased risk of postoperative complications. In a multivari-
able model, a low percent FEV1 (Odds ratio [OR], 19.6;
95% confidence interval [CI], 0.010-0.055; P ¼ .0035)
and reoperative ipsilateral surgery (OR, 4.66; 95% CI,
0.36-1.19; P ¼ .0002) were associated with increased risk
of postoperative complications.
The median follow-up was 28.7 months (range, 1.5-237
months) and follow-up was complete in 99.4% of patients.
The 5- and 10-year overall survival rates after the initial
lung cancer resection were 87.4% and 58.9%, respectively.ery c March 2013
TABLE 1. Characteristics andoperativedetails of 161patients surgically
treated for metachronous second primary non–small cell lung cancer
Characteristic Median Range
Age (y) 70 34-88
Interval between first and second operation (m) 42.7 7-205
Interval between first operation and first
postoperative surveillance CT scan (m)
8.7 0.5-208
Number of nodules 1 1-7
Tumor size (cm) 1.6 0.2-8.6
Pack years of smoking 40 4-150
n %
Sex
Man 88 54.7
Woman 73 45.3
Tobacco history
Never smoker 23 14.3
Current smoker 18 11.2
Former smoker 120 74.5
Quit before first operation 111
Quit after first operation 9
Histology of first NSCLC
Adenocarcinoma 105 65.2
Squamous cell carcinoma 37 23.0
Bronchoalveolar carcinoma 12 7.5
Large cell carcinoma 5 3.1
Adenosquamous cell carcinoma 1 0.6
Adenoid cystic carcinoma 1 0.6
Surgical approach first operation
Thoracotomy 150 93.2
Video-assisted thoracoscopic surgery 11 6.8
Extent of resection first operation
Lobectomy 126 78.3
Wedge 15 9.3
Segmentectomy 13 8.1
Pneumonectomy 7 4.3
TNM stage at first operation
IA 71 44
IB 50 31.1
IIA 7 4.3
IIB 17 10.6
IIIA 7 4.3
IIIB 2 1.2
IV 7 4.3
Surveillance after first operation
Chest radiograph 45 28
Computed tomography 116 72
Symptoms at diagnosis of second lung cancer
Asymptomatic 161 100
Symptomatic 0 0
Surgical approach for second operation
Video-assisted thorascopic surgery 35 21.7
Thoracotomy 126 78.3
Unilateral 160 99.4
Bilateral 1 0.6
Ipsilateral 48 29.8
Contralateral 113 70.2
(Continued)
TABLE 1. Continued
n %
Number of nodules
Single 132 82
Multiple 29 18
Extent of lung resection second operation
Wedge 97 60.2
Lobectomy 36 22.4
Segmentectomy 27 16.8
Completion pneumonectomy 1 0.6
Assessment of mediastinal lymph nodes
Cervical mediastinoscopy 18 11.2
Mediastinal lymphadenectomy or sampling 118 73.3
No surgical evaluation of mediastinal nodes 43 26.7
Mediastinal lymph node status
N0 104 64.6
N1 5 3.1
N2 9 5.6
NX 43 26.7
TNM stage at second operation
IA 111 68.9
IB 13 8.1
IIA 3 1.9
IIB 13 8.1
IIIA 6 3.7
IIIB 9 5.6
IV 8 4.9
Histology of second NSCLC
Same as first 123 76.4
Different 38 23.6
Histology of second NSCLC
Adenocarcinoma 98 60.9
Squamous cell carcinoma 41 25.5
Bronchoalveolar cell carcinoma 21 13.0
Adenoid cystic carcinoma 1 0.6
CT, Comptued tomography; NSCLC, non–small cell lung cancer; TNM, TNM classi-
fication of malignant tumors.
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SMedian survival after the first operation was 148.9 months
(range, 14-237 months). Overall 5- and 10-year survival rates
after resection of a metachronous second primary NSCLC
were 60.8% and 20.0%, respectively. The median survival
was 72.9 months (range, 2-130 months). Patients with stages
IA and IB MSPLC had an overall survival of 73.4% and
66.7%, respectively. In univariate analysis, the only factors
associated with shorter survival were tumor size >2 cm
(P ¼ .0001) and the number of pack years of smoking
(P ¼ .0005). In multivariate analysis, tumor size>2 cm
(OR, 7.70; 95% CI, 1.93-27.21; P ¼ .003) (Figure 1) and
the number of pack years of smoking (OR, 2.48; 95% CI,
1.37-4.54; P ¼ .005) were the only independent predictors
of inferior survival. Patient’s sex, smoking status (never vs cur-
rent vs former, quit before or after initial lung cancer resec-
tion), DFI, type of radiographic study used in follow-up
surveillance (CXR vs CT scan), if the patient was followed
by regular surveillance screening CT scans, percent predictedrdiovascular Surgery c Volume 145, Number 3 685
FIGURE 1. Kaplan-Meier estimates of survival after resection of a second
metachronous second primary lung cancer (MSPLC) based on tumor size
(P ¼ .003). NSCLC, Non–small cell lung cancer.
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of surgical resection, if the histology of the MSPLC was the
same or different from thefirst lung cancer, lymph node status,
TNMstage, and adenocarcinoma versus squamous cell histol-
ogy were not associated with shorter survival (Figure 2). The
5-year survival for a second metachronous NSCLC was
76.2% if the tumor size was 2cm compared with 37.4% if
the tumor sizewas>2 cm. Progression after pulmonary resec-
tion for a secondmetachronous NSCLCwas defined as a third
NSCLC (either a third primary, recurrence, or metastatic dis-
ease). The 5-year progression-free rate after pulmonary resec-
tion of a second metachronous NSCLC was 47.0%. The
median progression-free interval was 59.0months. Univariate
analysis showed only ipsilateral procedure (P¼ .037) and tu-
mor size>2 cm (P ¼ .002) as significant factors associated
with worse progression-free interval. In multivariate analysis
only tumor size>2 cm was a significant negative prognostic
factor for progression (P ¼ .003).
Sixty-nine patients developed progression of disease
with 57 (82.6%) developing intrathoracic disease (local)
and 12 (17.4%) developing extrathoracic spread (distant).
The median interval from a second NSCLC to progression
was 18 months, ranging from 1 to 112 months. Only 13
(22.8%) of the 57 patients who developed intrathoracic
disease underwent a third-time pulmonary resection for
progression.
Adjuvant therapy after a second operation was consid-
ered or recommended in 14 patients (8.7%). The indication
for adjuvant therapy was stage II or higher disease in 13
patients and a high clinical suspicion for recurrent NSCLC
in 1 patient. However, adjuvant therapy was not performed
due to medical comorbidities in 8 patients and 2 patients
refused therapy. Cisplatinum-based chemotherapy was
used in 2 patients, radiotherapy in 1 patient, and combined
chemoradiotherapy in 1 patient. Forty-three patients’
cancer out of 161 were stage II or higher. Of these 43
patients, adjuvant therapy was given in 4 patients as detailed686 The Journal of Thoracic and Cardiovascular Surgabove but failed to provide a statistically significant im-
provement survival after a second metachronous NSCLC
(P ¼ .140).
DISCUSSION
Distinguishing MSPLC from recurrence or metastatic
disease is important because the prognosis and treatment
are dramatically different. We have shown previously that
in patients who developed recurrent disease, survival was
51.8% at 2 years in patients with a MSPLC compared
with 24.3% in those with local recurrence and only 8.9%
in thosewith nonregional metastases.4 Surgical resection re-
mains themost effective treatment for patients withNSCLC,
with 5-year survival rates approaching 70% at 5 years and
60% at 10 years.7 Often patients who haveMSPLC are con-
sidered to have more advanced disease and are not offered
surgical resection, which negatively affects their survival.
In this study, we report the largest series to date of surgi-
cally treated MSPLC. We have shown that patients with
stages IA and IB MSPLC who were surgically treated had
a 3-year survival of 73.4% and 66.7%, respectively. This
compares favorably to patients with single lung cancers
when matched for stage.7 The 5- and 10-year survival rates
of 60.8% and 20% we found in our study are somewhat
higher thanwhat other investigators have reported. In a report
on 51 patients who underwent surgical treatment of second
primary lung cancers, Aziz and colleagues8 reported a
5-year survival for patients with metachronous second pri-
mary lung cancer of 44%. Similarly Adebonojo and col-
leagues3 reported a 5-year survival of 37% in 37 patients
who underwent resection of metachronous second primary
lung cancers at the Walter Reed Army Medical Center. One
possible explanation for this difference in results is that no
uniform agreement exists as towhat constitutes a second pri-
mary lung cancer and a variety of different criteria are used.
The most commonly used criteria to define metachronous
lung cancers were proposed by Martini and Melamed in
1975.9 These criteria recommend that for lesions of similar
histology, if there is no evidence of lymph node metastases
in the common drainage basins and in the absence of extra-
thoracic metastases, it is reasonable to treat patients for sec-
ond primary disease. These criteria have proven to be
durable and have been used in a number of other surgical
series of patients treated surgically for MSPLC.10 In our
study we used the same criteria to define MPLCs that we
used in our previous reports on MPLCs, which are a modifi-
cation of the criteria originally set forth byMartini andMel-
amed. Using these criteria, the overall incidence of MSPLC
of 5.1% in our series is similar to what other surgical
series have reported.5,8 Although some would argue
that distinguishing MSPLC from local recurrence or
metastatic disease using any criteria is an impossible task,
if extrathoracic metastases can be excluded and the
patient can tolerate a second or third pulmonary resection,ery c March 2013
FIGURE 2. Kaplan-Meier estimates of survival after a second metachronous second primary lung cancer (MSPLC) based on histology, sex, modality of
surveillance, lymph node status, extent of resection, disease-free interval (DFI), and adenocarcinoma versus squamous cell histology (P ¼ .09).
NSCLC, Non–small cell lung cancer; CT, computed tomography; CXR, chest radiograph.
Hamaji et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery c Volume 145, Number 3 687
G
T
S
General Thoracic Surgery Hamaji et al
G
T
Swe believe surgery should be considered because resection
may offer the best chance for potential cure.
There was no operative mortality in our series and the
surgical morbidity for this group of patients compares
very favorably to several large contemporary multi-
institutional reports of patients undergoing major pulmo-
nary resection for NSCLC. Postoperative complications of
any kind occurred in 29.2% of patients in this study, which
is lower than the 38% complication rate reported in both
groups of patients who participated in the randomized, pro-
spective American College of Surgeons Oncology Group
Z0030 trial of lymph node sampling versus mediastinal
lymph node dissection for early stage lung cancer.11 Simi-
larly, using the definition of major morbidity set forth in
a recent study of the Society of Thoracic Surgeons General
Thoracic Database, the major morbidity rate for patients in
this study was 5.6% compared with a major morbidity rate
of 7.9% among the 18,800 patients who underwent lung
cancer operations between January 1, 2002, and June 30,
2008, performed at 111 participating centers.12 These re-
sults are somewhat surprising because one might intuitively
expect to find a higher mortality and morbidity rate in this
group of patients compared with patients undergoing pri-
mary lung cancer surgery. This is particularly the case given
the reoperative nature of a second, and in some cases, third
operation in patients who had already undergone substantial
prior lung resection. Of the 161 patients in this study, 78.3%
had undergone prior lobectomy and 4.3% had undergone
pneumonectomy. In addition, 30% of patients underwent
reoperative surgery on the ipsilateral side. Multivariate
analysis did show that lower predicted FEV1 and reopera-
tion in the ipsilateral side of the chest as the first operation
were predictors of a higher risk of postoperative complica-
tions. Our results are difficult to compare with other pub-
lished surgical series of MPLCs because none of the other
large series have analyzed postoperative complications, fo-
cussing exclusively on operative mortality. The generaliz-
ability of our favorable results in this group of complex
patients also needs to be tempered by an acknowledgment
that the patients in our series were highly selected and re-
sults obtained in a highly specialized practice such as ours
may not be broadly applicable to other practice settings.
To identify factors associated with improved survival,
univariate and multivariate analysis of a large number of
clinical variables was performed. On multivariate analysis,
only tumor size>2 cm and number of pack years of smoking
were independent predictors of worse survival after resec-
tion of a MSPLC. These results are both novel findings.
Our finding that the 2 cmcutpointwas such a strong indepen-
dent predictor of survival is supported by the recent changes
to the T-stage descriptor implemented by the International
Association for the Study of Lung Cancer in the seventh edi-
tion of the TNM classification for lung cancer.7,13 T1 tumors
were subdivided into 2 prognostic groups: those 2 cm688 The Journal of Thoracic and Cardiovascular Surg(T1a) and those larger than 2 cm but no larger than 3 cm
(T1b). Our finding that smaller tumors have a favorable
survival should highlight the need for close follow-up of pa-
tients with resected NSCLC with CT scanning. Although
smoking status has not been analyzed as an independent
predictor of survival in previous studies of MSPLC,3,8,14
smoking status has been shown to be a significant
independent prognostic factor predictive of inferior long-
term survival in patients undergoing surgery for
NSCLC.15,16 There are a number of possible explanations
for these observations. Smoking is associated with many
factors that may contribute to worse cancer survival: lower
socioeconomic status, poorer nutrition, comorbidity,
impaired immune function, and exposure to oncogenic
substances that result in an increased mutation burden that
may lead to accelerated carcinogenesis and progression.
Of these, comorbidity may be one of the most important
factors because smoking is associated with numerous
serious other diseases in addition to lung cancer. The US
Surgeon General concluded that smoking accounts for
82% of chronic obstructive pulmonary disease-related
deaths, 21% of coronary heart disease-related deaths, and
18% of deaths from stroke.17
In their original 1975 publication describing the
Memorial-Sloan Kettering experience with 32 patients
with MSPLC, Martini and Melamed9 proposed that for tu-
mors of the same histology that a DFI of at least 2 years
was required to be considered a metachronous lung cancer.
Using these criteria, in their 1991 follow-up report on 78 pa-
tients with MSPLC, they found that survival was signifi-
cantly better when the interval between 2 metachronous
tumors was 24 months.18 We modified the criteria pro-
posed by Martini and Melamed to define metachronous
tumors by eliminating the requirement of a DFI of at least
2 years to be able to validate if that criteria is associated
with survival. We analyzed DFIs of 2, 3, and 5 years as
well as if the DFI was<2 years or 2 years, and did not
find any association with survival. This suggests to us that
a DFI of at least 2 years should not be used as strict criteria
to distinguish metachronous lung cancer from more ad-
vanced states of disease.
Continued and careful long-term follow-up is necessary
for all patients who have undergone resection of primary
NSCLC and is the mainstay of diagnosis of MSPLC.
Even after curative resection of a NSCLC, it is estimated
that the risk of developing a second MSPLC is 1% to 2%
per patient per year.19-21 In some series 68% to 100%
of patients with metachronous lung cancers were
asymptomatic and had the new primary cancer detected
by radiographic methods.14,22,23 In our series all of the
patients were asymptomatic and had the MSPLC detected
by CXR or CT scan. Close follow-up with radiographic
studies are particularly important during the first 3 years fol-
lowing resection of NSCLC because some series haveery c March 2013
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during this time.14 Our data was consistent with this, as
44% of 161 patients developed a MSPLC within the first
3 years following resection of the primary NSCLC. We rec-
ommend lifelong close follow-up of patients who have un-
dergone resection of NSCLC because a MSPLC developed
in 33.6% of the patients our studymore than 5 years follow-
ing their first NSCLC operation and in 6.9% of patients
more than 10 years later. This is consistent with what other
investigators have found. Mathisen and colleagues14 found
that 25% of patients developed a second primary more than
5 years after the first primary cancer was resected, and
Temeck and colleagues24 found a 16% incidence of second
lung primaries in patients who survived 10 years.
Results from the National Cancer Institute sponsored ran-
domized phase III National Lung Screening Trial for the
first time has provided level-1 evidence that low-dose chest
CT screening reduced lung cancer-specific mortality by
20% in a patient population believed to be at high risk for
lung cancer.25 Interestingly, in our study we found that sur-
vival following surgical treatment of a MSPLC was not as-
sociated with follow-up with CT scan or CXR. We suspect
that this is due to the relatively small number of patients in
our study. The National Lung Screening Trial randomized
53,454 patients, and was the first randomized trial to ever
demonstrate efficacy of a low-dose chest CT screening
program.
Although 5 different medical societies (ie, American
College of Chest Physicians, American College of Radiol-
ogy, American Society of Clinical Oncology, European So-
ciety for Medical Oncology, and National Comprehensive
Cancer Network) have put forward guidelines providing
specific recommendations for surveillance methods in pa-
tients treated for NSCLC,21 there is wide divergence among
the guidelines regarding recommendations for chest imag-
ing. Whereas European Society for Medical Oncology
and American Society of Clinical Oncology guidelines do
not recommend any chest imaging, the American College
of Radiology recommends a CXR every 2 to 4 months
and a CT scan every 12 months. The American College of
Chest Physicians guidelines recommend a CXR or CT
scan every 6 months, and the National Comprehensive Can-
cer Network guidelines recommend a CT scan every 6
months. Because the issues of radiographic detection of
asymptomatic recurrent or metachronous cancer after treat-
ment with curative intent are similar to those of early detec-
tion of primary cancer with screening programs in high-risk
patients, we believe that the data from the National Lung
Screening Trial can be extrapolated to justify close surveil-
lance of patients treated for NSCLCwith low-dose chest CT
scan. However, we do not believe there is sufficient evi-
dence at present to make any recommendations about spe-
cific practice guidelines regarding the frequency of the
imaging studies.The Journal of Thoracic and CaThere are several important potential limitations of this
study. This was a single institution experience, and as is
the case with analysis of all single institution studies, the is-
sue of external validity is relevant. Futhermore, due to the
retrospective nature of the study, the results are based on
a highly selected group of patients, and there is certainly
a degree of selection bias in the study. We only analyzed pa-
tients who were surgically treated, and therefore are unable
to compare the outcomes of this group with patients with
MSPLC who were never offered or refused surgery and
were treated medically. Finally, the incidence of MSPLC
is still relatively low, and many of the subgroups we ana-
lyzed to identify covariates associated with survival had
low numbers of patients. The low numbers within these sub-
groups may explain the lack of statistical difference in sur-
vival between patients with nodal metastases and those
whose cancers were TNM stage N0, higher- versus lower-
stage disease, and the extent of resection.CONCLUSIONS
In selected patients, surgical treatment of a second meta-
chronous NSCLC can be undertaken with 5-year expected
survival rates of 60%. Expected morbidity and mortality
are not inherently worse when compared with patients
undergoing primary surgery and should not be used to
deny patients who can tolerate additional resection poten-
tially curative surgical therapy. Tumor size 2 cm or smaller
is a predictor of improved survival and lower rates of pro-
gression in patients undergoing surgical treatment of
MSPLC. For a metachronous NSCLC, sublobar resection
is acceptable when anatomically possible. Close, lifelong
follow-up is recommended for all patients who have under-
gone resection of lung cancer. Any new developments
should be aggressively investigated to try to distinguish
between local recurrence or metastases.References
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Dr Paul H. Schipper (Portland, Ore). I would like to know
more about how I can use this data set clinically, so I have 2 ques-
tions for you. The first question has to dowith the 42-month or 3.5-
year median interval between the first and second surgery. This is
a retrospective case series, an inherent problem of which is that
you are not the first person to screen the data. The data is in fact
first screened by the surgeon who made the decision to operate
or not to operate on this person a second time. I think the surgeons
at the Mayo Clinic probably had a couple things in mind as they
were making this decision. One is the Martini and Melamed crite-
ria of a 2-year interval to consider something a new primary versus
a recurrence. The second is that statistically most recurrences hap-
pen in that first 2 years, and the final is that at least I feel more com-
fortable with a trial of time. I can say to myself, okay, it has been 2690 The Journal of Thoracic and Cardiovascular Surgyears and this is the only disease we see—let’s apply this local
therapy of surgery.
So, based on your data can you make any suggestions as to what
I should do with a 1.5-cm lesion showing up 6 months or 1 year
from the initial lesion? Do you think that this 3.5-year period is
selecting for slower-growing, biologically less active tumors?
Dr Hamaji. Although Martini and Melamed in their original
1975 publication proposed that, for tumors of the same histology,
a DFI of at least 2 years was required to be considered a metachro-
nous lung cancer, we specifically eliminated the requirement of
a DFI of at least 2 years when selecting patients for this study to
be able to validate if that criteria is associated with survival. We
did not find any association of DFI with survival, so if the patient
is medically fit and can tolerate additional surgery and you believe
that the second lesion is an MSPLC and not local recurrence or
a metastasis, we would recommend surgical resection.
Dr Schipper.And that 3.5-year period? Maybe the patients that
you are presenting to us have tumors that are less biologically
active? Or in other words, these patients made it through that
3.5-year period. Maybe there is another subset of patients who
did not and the surgeons at Mayo said to themselves, ‘‘Your tumor
showed up 6 months after an operation, this is an aggressive tumor,
maybe I should not apply local therapy, maybe you would be better
served with chemotherapy or radiation therapy.’’ Those patients,
therefore, did not make it into the study.
Dr Hamaji. We analyzed the DFIs of 2 years, 3 years, and 5
years, and compared patients with DFIs<2 years and patients
with DFIs>2 years, and we did not find a significant difference
in survival. We did the same analysis for the 3 years and 5 years
patients, so we did not use the time range for patient selection.
Our recommendation is unless the patient has ground-glass opacity
we will be very aggressive for surgical management of the lung
nodule.
Dr Schipper. So anywhere from 2 to 5 years after your first
operation is okay,<2 years is still questionable? Would you agree
with that?
Let me ask my second question. You talk about surveillance im-
aging and your conclusion is that you recommend surveillance im-
aging. One of the things you point out is that in your analysis of the
patients who had surveillance versus those that did not, there was
no difference in survival and that in a significant group of your pa-
tients the tumor was found by chance. Meanwhile, 100% of the pa-
tients you operated on were asymptomatic. Although I agree with
the need for surveillance, I am curious as to how you came to that
conclusion using your data.
Dr Hamaji. Before our analysis we expected that chest com-
puted tomography (CT) surveillance would be superior to x-ray
surveillance but actually we failed to show chest CT’s advantage.
The reason, we think, is because of our small number of patients.
Theoretically chest CT is superior in picking up a smaller nodule,
which we showed is a significant factor in better survival after
a second lung cancer, so we recommend chest CT for surveillance.
Dr Frederic Grannis (Duarte, Calif). John Benfield, a former
president of this organization, many years ago showed an enor-
mous risk of second lung cancer and also head and neck cancer fol-
lowing treatment of a tobacco-related cancer. Based on that, we
have been doing annual CT scans in all of our survivors for almost
30 years now. Jeff Lemont published that data and showed that theery c March 2013
Hamaji et al General Thoracic Surgerysurveillance benefit of a CT scan is very minor, but the screening
benefit is enormous. We reported 85% detection of second lung
cancers in stage 1A and 70% alive at 4 years.
Now to the question. The recent American Association for Tho-
racic Surgery meeting gave a guideline recommendation that we
should be screening all patients with a first lung cancer and I agree
with that, but we cannot tell from your data the characteristics of
the patients who had a second lung cancer but were not operatedThe Journal of Thoracic and Ca
T
Son. Can you tell us how many such patients there were and what
were the survival and screening characteristics of the other group
of patients who were not operated on?
Dr Hamaji. We only analyzed patients who had second lung
cancer surgery and we did not look into patients who were man-
aged medically and we did not compare the 2 patient groups, so
I do not have any information on the patients with MSPLC who
did not undergo surgical treatment.rdiovascular Surgery c Volume 145, Number 3 691
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